<html xmlns="http://www.w3.org/1999/xhtml"><body><table class="table"><caption /><tr><th class="cell">Study type (CONSORT/STROBE) </th><th class="cell">Main cancer class </th><th class="cell">CIPN severity report (count by grade if given) </th><th class="cell">CIPN assessment time points </th><th class="cell">CIPN assessment method(s) </th></tr><tr><td class="cell">Von Schlippe (2001)</td><td class="cell">Prospective cohort</td><td class="cell">Testicular</td><td class="cell">Grade I (4/5)</td><td class="cell">Unclear if at baseline</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Grade II (1/5)</td><td class="cell">Every 6 wk for first 6 mo after chemotherapy</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Thereafter every 2 mo for median of 4 y (range</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">2–8 y)</td><td class="empty"></td></tr><tr><td class="cell">Cisplatin or carboplatin and paclitaxel: 73% (95% CI = 36.2–109.7)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Argyriou (2007)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple solid</td><td class="empty"></td><td class="empty"></td><td class="cell">Mild (2/9)</td><td class="cell">Baseline</td><td class="cell">PNS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Moderate (6/9)</td><td class="cell">Cycle 3, 6</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Severe (1/9)</td><td class="cell">3 mo after chemo end</td><td class="empty"></td></tr><tr><td class="cell">Kawakami (2012) ^{§}</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Lung</td><td class="empty"></td><td class="empty"></td><td class="cell">% Severity with</td><td class="cell">Baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">cumulative dose</td><td class="cell">Daily during cycle 1</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Cycle 2, 3, 4</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Chemo end</td><td class="empty"></td></tr><tr><td class="cell">Cisplatin and vincristine: 20.1% (95% CI = -26.2 to 66.5)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Glendenning (2010) ^{§}</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Cross-sectional</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Testicular</td><td class="empty"></td><td class="empty"></td><td class="cell">Only grade P3 reported</td><td class="cell">Recruited patients at least 5 y post-treatment</td><td class="cell">(EORTC) QLQ-C30</td></tr><tr><td class="cell">cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Assessed once for this prevalence study</td><td class="cell">NES</td></tr><tr><td class="cell">Paclitaxel: 70.8% (95% CI = 43.5–98.1)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Argyriou (2006) ^{‡}</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Breast</td><td class="empty"></td><td class="empty"></td><td class="cell">Reported by age group</td><td class="cell">Baseline</td><td class="cell">PNS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">only</td><td class="cell">Cycles 3, 6</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">3 mo after chemo end</td><td class="empty"></td></tr><tr><td class="cell">Baldwin (2012)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Breast</td><td class="empty"></td><td class="empty"></td><td class="cell">Only grade P2 reported</td><td class="cell">Unclear if at baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Cycles 4, 6</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Within 1 mo of chemo end</td><td class="empty"></td></tr><tr><td class="cell">Ghoreishi (2012)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">RCT</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Breast</td><td class="empty"></td><td class="empty"></td><td class="cell">Mild (10/16)</td><td class="cell">Baseline</td><td class="cell">TNSc</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Moderate (5/16)</td><td class="cell">1 mo after chemo end</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Severe (1/16)</td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Pace (2007)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Breast</td><td class="empty"></td><td class="empty"></td><td class="cell">Mean neurotoxicity scores</td><td class="cell">Baseline</td><td class="cell">TNSc</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">reported</td><td class="cell">After 12 wk of chemo</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">After 24 wk of chemo</td><td class="empty"></td></tr><tr><td class="cell">Vincristine: 19.6% (95% CI -26.6 to 65.9)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Johnson (2011) ^{‡}</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">RCT</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade P I 31.8%</td><td class="cell">Unclear if at baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="cell">myeloma</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade P II 11%</td><td class="cell">At each cycle</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Grade P III 3.6%</td><td class="cell">For 6 months after chemo end for induction (ie,</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">36 wk from start of induction therapy)</td><td class="empty"></td></tr><tr><td class="cell">Thalidomide: 63.5% (95% CI = 29.3–97.8)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Johnson (2011) ^{‡}</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">RCT</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade details not reported</td><td class="cell">Unclear if at baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="cell">myeloma</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">At each cycle</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">For 6 mo after end of chemo for induction (ie,</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">36 weeks from start of induction therapy)</td><td class="empty"></td></tr><tr><td class="cell">Plasmati (2002)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade I (12/24)</td><td class="cell">Baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="cell">myeloma</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade II (6/24)</td><td class="cell">After 4 mo of chemo</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Subclincial (6/24)</td><td class="cell">3 mo after stem cell transplantation</td><td class="empty"></td></tr><tr><td class="cell">Bortezomib: 46.7% (95% CI = 0.3–93.1)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Dimopoulos (2011)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">RCT</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade I NR</td><td class="cell">Unclear if at baseline</td><td class="cell">NCI-CTC</td></tr><tr><td class="cell">myeloma</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade II (64/159)</td><td class="cell">Every 3 wk until</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Grade III (45/159)</td><td class="cell">1 mo after last chemo dose</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Grade IV (1/159)</td><td class="cell">Longer follow-up but no denominator data</td><td class="empty"></td></tr><tr><td class="cell">Bortezomib and thalidomide: 96.2% (95% CI = 49.7–143)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Chaudhary (2008)</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Prospective cohort</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td></tr><tr><td class="cell">Multiple</td><td class="empty"></td><td class="empty"></td><td class="cell">Grade P2 reported</td><td class="cell">Baseline</td><td class="cell">TNSc</td></tr><tr><td class="cell">myeloma</td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Cycles 2, 4, 6, 8</td><td class="cell">NPS</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">End of chemo</td><td class="cell">Skin biopsy</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Note skin biopsy at baseline and end of chemo</td><td class="empty"></td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">only</td><td class="empty"></td></tr></table></body></html>